Barclays PLC Buys 19,891 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)

Barclays PLC increased its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 48.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,130 shares of the company’s stock after acquiring an additional 19,891 shares during the quarter. Barclays PLC owned about 0.13% of Cabaletta Bio worth $288,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of Cabaletta Bio by 35.7% in the second quarter. Rhumbline Advisers now owns 61,880 shares of the company’s stock worth $463,000 after purchasing an additional 16,274 shares during the period. Westwood Holdings Group Inc. lifted its stake in shares of Cabaletta Bio by 106.9% during the 2nd quarter. Westwood Holdings Group Inc. now owns 170,129 shares of the company’s stock valued at $1,273,000 after buying an additional 87,901 shares in the last quarter. Marshall Wace LLP increased its stake in Cabaletta Bio by 92.9% in the 2nd quarter. Marshall Wace LLP now owns 330,187 shares of the company’s stock worth $2,470,000 after buying an additional 159,000 shares in the last quarter. Squarepoint Ops LLC increased its stake in Cabaletta Bio by 643.3% in the 2nd quarter. Squarepoint Ops LLC now owns 315,379 shares of the company’s stock worth $2,359,000 after buying an additional 272,948 shares in the last quarter. Finally, AXA S.A. raised its holdings in Cabaletta Bio by 52.0% during the second quarter. AXA S.A. now owns 270,778 shares of the company’s stock valued at $2,025,000 after acquiring an additional 92,616 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on CABA shares. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. William Blair restated an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. UBS Group assumed coverage on shares of Cabaletta Bio in a research report on Thursday, October 10th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a research note on Friday. Finally, Evercore ISI downgraded shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and reduced their price target for the company from $15.00 to $6.00 in a report on Friday, December 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $24.38.

Cabaletta Bio Stock Up 12.8 %

CABA stock opened at $2.74 on Tuesday. The company has a fifty day simple moving average of $2.75 and a two-hundred day simple moving average of $4.38. Cabaletta Bio, Inc. has a 52 week low of $1.76 and a 52 week high of $26.35. The firm has a market capitalization of $133.93 million, a P/E ratio of -1.27 and a beta of 2.46.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.